Q3 Loss Narrower Than Expected as Avalo Beats Consensus by $8M
AVTX is trading near its 52-week low of $6.53 (5.8% above the low).
Summary
Avalo posted a Q3 net loss of $18.95M, well below the $27.20M consensus from nine analysts, a clear beat. Operating expenses still rose to $23.40M on higher manufacturing spend for AVTX-010 and abdakibart plus higher stock-based compensation and personnel costs. The company says its cash and investments fund operations into 2029, and it plans to start a Phase 3 trial of abdakibart in hidradenitis suppurativa in H1 2027, with an IND for AVTX-010 also targeted for H1 2027. This follows the 10-Q filed today and the $200M at-the-market program with Jefferies, which gives Avalo a large dilution tool alongside the improved loss figure. The key question is whether the narrower loss and 2029 runway hold up as the company ramps spending into late-stage development.
At the time of this announcement, AVTX was trading at $6.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $379.2M. The 52-week trading range was $6.53 to $24.27. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.